2023 - Research.com Medicine in United Kingdom Leader Award
2022 - Research.com Best Scientist Award
2022 - Research.com Medicine in United Kingdom Leader Award
2005 - King Faisal Prize
2004 - Member of the National Academy of Medicine (NAM)
2002 - Charles S. Mott Prize, General Motors Cancer Research Foundation
2000 - Prince Mahidol Award
1992 - Canada Gairdner International Award
1989 - Fellow of the Royal Society, United Kingdom
Fellow of The Academy of Medical Sciences, United Kingdom
Richard Peto focuses on Internal medicine, Surgery, Myocardial infarction, Breast cancer and Stroke. His Internal medicine study integrates concerns from other disciplines, such as Oncology and Cardiology. Richard Peto interconnects Rate ratio, Incidence and Cause of death in the investigation of issues within Surgery.
His Myocardial infarction research is multidisciplinary, relying on both Diabetes mellitus, Simvastatin, Placebo and Statin. His studies in Breast cancer integrate themes in fields like Relative risk, Gynecology, Radiation therapy and Chemotherapy. His Stroke research is multidisciplinary, incorporating elements of Aspirin, Physical therapy and Cholesterol.
The scientist’s investigation covers issues in Internal medicine, Prospective cohort study, Surgery, Demography and Oncology. Blood pressure is closely connected to Cardiology in his research, which is encompassed under the umbrella topic of Internal medicine. Richard Peto has researched Prospective cohort study in several fields, including Body mass index, Epidemiology, Diabetes mellitus, Relative risk and Proportional hazards model.
Many of his studies on Surgery involve topics that are commonly interrelated, such as Clinical trial. His research integrates issues of Cause of death, Gerontology and China in his study of Demography. His Oncology research is multidisciplinary, incorporating perspectives in Tamoxifen, Chemotherapy and Early breast cancer.
Richard Peto mainly focuses on Internal medicine, Prospective cohort study, Demography, Proportional hazards model and Diabetes mellitus. As part of his studies on Internal medicine, Richard Peto often connects relevant subjects like Oncology. His Prospective cohort study study combines topics in areas such as Incidence, Relative risk, Mortality rate, Hazard ratio and Pediatrics.
His research on Demography also deals with topics like
Internal medicine, Prospective cohort study, Demography, Stroke and Gerontology are his primary areas of study. His biological study spans a wide range of topics, including Surgery and Oncology. Richard Peto combines subjects such as Smoking cessation, Relative risk, Mortality rate, Cause of death and Proportional hazards model with his study of Prospective cohort study.
His Demography research incorporates elements of Substance abuse and Hazard ratio. His Stroke study incorporates themes from Diabetes mellitus, Cardiovascular disease in China, Family medicine, Vascular disease and Myocardial infarction. His study in Breast cancer is interdisciplinary in nature, drawing from both Radiation therapy and Disease.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
R C Turner;R R Holman;C A Cull;I M Stratton.
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.
Sarah Lewington;Robert Clarke;Nawab Qizilbash;Richard Peto.
The Lancet (2002)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
O. Abe;R. Abe;K. Enomoto;K. Kikuchi.
The Lancet (2005)
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
C Baigent;C Sudlow;R Collins;R Peto.
The Causes of Cancer: Quantitative Estimates of Avoidable Risks of Cancer in the United States Today
Richard Doll;Richard Peto.
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
C Baigent;A Keech;P M Kearney;L Blackwell.
The Lancet (2005)
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.
R Peto;M C Pike;P Armitage;N E Breslow.
British Journal of Cancer (1977)
COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
R Altman;L Carreras;R Diaz;E Figueroa.
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
C Baigent;L Blackwell;J Emberson.
The Lancet (2010)
Tamoxifen for early breast cancer: An overview of the randomised trials
M Clarke;R Collins;C Davies.
The Lancet (1998)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: